Acknowledgement
Supported by : 대한아토피피부염학회
References
- Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol 2011;131:67-73 https://doi.org/10.1038/jid.2010.251
- Drucker AM. Atopic dermatitis: burden of illness, quality of life, and associated complications. Allergy Asthma Proc 2017;38:3-8
- Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol 2018;120:10-22 https://doi.org/10.1016/j.anai.2017.10.039
- Silverberg JI. Healthcare utilization, patient costs, and access to care in US adults with eczema: a population-based study. JAMA Dermatol 2015;151:743-752 https://doi.org/10.1001/jamadermatol.2014.5432
- Lee SH, Lee SH, Lee SY, Lee B, Lee S-H, Park YL. Psychological health status and health-related quality of life in adults with atopic dermatitis: A nationwide crosssectional study in South Korea. Acta Derm Venereol 2018;98:89-97 https://doi.org/10.2340/00015555-2797
- Elias PM, Eichenfield LF, Fowler J, Horowitz P, McLeod RP. Update on the structure and function of the skin barrier: atopic dermatitis as an exemplar of clinical implications. Semin Cutan Med Surg 2013;32:S21-S24 https://doi.org/10.12788/j.sder.0022
- Simpson E, Trookman NS, Rizer RL, Preston N, Colon LE, Johnson LA, et al. Safety and tolerability of a body wash and moisturizer when applied to infants and toddlers with a history of atopic dermatitis: results from an open-label study. Pediatr Dermatol 2012;29:590-597 https://doi.org/10.1111/j.1525-1470.2012.01809.x
- Kim JE, Kim HJ, Lew B-L, Lee KH, Hong SP, Jang YH, et al. Consensus guidelines for the treatment of atopic dermatitis in Korea (part I): general management and topical treatment. Ann Dermatol 2015;27:563-577 https://doi.org/10.5021/ad.2015.27.5.563
- Sakai T, Hatano Y, Zhang W, Fujiwara S. Defective maintenance of pH of stratum corneum is correlated with preferential emergence and exacerbation of atopic-dermatitis-like dermatitis in flaky-tail mice. J Dermatol Sci 2014;74:222-228 https://doi.org/10.1016/j.jdermsci.2014.01.012
- Lee HJ, Lee SH. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol Res 2014;6:276-287 https://doi.org/10.4168/aair.2014.6.4.276
- Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018;32:657-682 https://doi.org/10.1111/jdv.14891
- Katayama I, Kohno Y, Akiyama K, Aihara M, Kondo N, Saeki H, et al. Japanese guideline for atopic dermatitis 2014. Allergol Int 2014;63:377-398 https://doi.org/10.2332/allergolint.14-RAI-0769
- Jeong KY, Park JW, Hong CS. House dust mite allergy in Korea: the most important inhalant allergen in current and future. Allergy Asthma Immunol Res 2012;4:313-325 https://doi.org/10.4168/aair.2012.4.6.313
- Lopes C, Silva D, Delgado L, Correia O, Moreira A. Functional textiles for atopic dermatitis: a systematic review and meta-analysis. Pediatr Allergy Immunol 2013;24:603-613 https://doi.org/10.1111/pai.12111
- Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012;26:1045-1060 https://doi.org/10.1111/j.1468-3083.2012.04635.x
- Barbarot S, Bernier C, Deleuran M, De Raeve L, Eichenfield L, El Hachem M, et al. Therapeutic patient education in children with atopic dermatitis: position paper on objectives and recommendations. Pediatr Dermatol 2013;30:199-206 https://doi.org/10.1111/pde.12045
- Boralevi F, Saint Aroman M, Delarue A, Raudsepp H, Kaszuba A, Bylaite M, et al. Long-term emollient therapy improves xerosis in children with atopic dermatitis. J Eur Acad Dermatol Venereol 2014;28:1456-1462 https://doi.org/10.1111/jdv.12314
- Sher LG, Chang J, Patel IB, Balkrishnan R, Fleischer Jra AB. Relieving the pruritus of atopic dermatitis: a meta-analysis. Acta Derm Venereol 2012;92:455-461 https://doi.org/10.2340/00015555-1360
- Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002;147:528-537 https://doi.org/10.1046/j.1365-2133.2002.05006.x
- Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992;27:29-34 https://doi.org/10.1016/0190-9622(92)70151-5
- Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician 2009;79:135-140
- Dekio I, Morita E. The weight of a finger-tip unit of ointment in 5-gram tubes. J Dermatolog Treat 2011;22:302-303 https://doi.org/10.3109/09546631003797098
- Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra F, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. Bmj 2003;326:1367 https://doi.org/10.1136/bmj.326.7403.1367
- Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011;164:415-428 https://doi.org/10.1111/j.1365-2133.2010.10030.x
- Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54:1-15; quiz 16-18 https://doi.org/10.1016/j.jaad.2005.01.010
- Janmohamed SR, Oranje AP, Devillers AC, Rizopoulos D, van Praag MC, Van Gysel D, et al. The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2014;70:1076-1082 https://doi.org/10.1016/j.jaad.2014.01.898
- Albarran-Planelles C, Jimenez-Gallo D, Linares-Barrios M, Martinez-Rodriguez A. Our experience with wet-wrap treatment. Actas Dermosifiliogr 2014;105:e18-21 https://doi.org/10.1016/j.ad.2013.11.004
- Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014;71:116-132 https://doi.org/10.1016/j.jaad.2014.03.023
- Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: metaanalysis of randomised controlled trials. Bmj 2005;330:516 https://doi.org/10.1136/bmj.38376.439653.D3
- Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat 2010;21:144-156 https://doi.org/10.3109/09546630903401470
- Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev 2015:Cd009864
- Reitamo S, Rustin M, Harper J, Kalimo K, Rubins A, Cambazard F, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol 2008;159:942-951 https://doi.org/10.1111/j.1365-2133.2008.08747.x
- Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics 2015;135:597-606 https://doi.org/10.1542/peds.2014-1990
- Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology 2002;204:63-68
- Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007;214:289-295 https://doi.org/10.1159/000100879
- Margolis DJ, Abuabara K, Hoffstad OJ, Wan J, Raimondo D, Bilker WB. Association Between Malignancy and Topical Use of Pimecrolimus. JAMA Dermatol 2015;151:594-599 https://doi.org/10.1001/jamadermatol.2014.4305
- Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 2016;75:494-503.e496 https://doi.org/10.1016/j.jaad.2016.05.046
- Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. Journal of the American Academy of Dermatology 2014;71:327-349 https://doi.org/10.1016/j.jaad.2014.03.030
- Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. British Journal of Dermatology 2003;148:1212-1221 https://doi.org/10.1046/j.1365-2133.2003.05293.x
- Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018;32:850-878 https://doi.org/10.1111/jdv.14888
- Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 2012;26:1176-1193 https://doi.org/10.1111/j.1468-3083.2012.04636.x
- Boguniewicz M, Sampson H, Leung SB, Harbeck R, Leung DY. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. Journal of Allergy and Clinical Immunology 2001;108:651-652 https://doi.org/10.1067/mai.2001.118598
- Kim JE, Kim HJ, Lew B-L, Lee KH, Hong SP, Jang YH, et al. Consensus guidelines for the treatment of atopic dermatitis in Korea (part II): systemic treatment. Annals of dermatology 2015;27:578-592 https://doi.org/10.5021/ad.2015.27.5.578
- Mayser P, Kupfer J, Nemetz D, Schafer U, Nilles M, Hort W, et al. Treatment of head and neck dermatitis with ciclopiroxolamine cream-results of a double-blind, placebo-controlled study. Skin pharmacology and physiology 2006;19:153-158 https://doi.org/10.1159/000092596
- Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo K. Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts. Allergy 2001;56:512-517 https://doi.org/10.1034/j.1398-9995.2001.056006512.x
- Forte WN, Sumita JM, Rodrigues AG, Liuson D, Tanaka E. Rebound phenomenon to systemic corticosteroid in atopic dermatitis. Allergologia et immunopathologia 2005;33:307-311 https://doi.org/10.1016/S0301-0546(05)73248-1
- Schmitt J, Schakel K, Folster-Holst R, Bauer A, Oertel R, Augustin M, et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebocontrolled multicentre trial. British Journal of Dermatology 2010;162:661-668 https://doi.org/10.1111/j.1365-2133.2009.09561.x
- Daley-Yates PT, Richards DH. Relationship between systemic corticosteroid exposureand growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model. Clinical therapeutics 2004;26:1905-1919 https://doi.org/10.1016/j.clinthera.2004.11.017
- Czech W, Brautigam M, Weidinger G, Schopf E. A bodyweight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. Journal of the American Academy of Dermatology 2000;42:653-659
- El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. European journal of pediatrics 2013;172:351-356 https://doi.org/10.1007/s00431-012-1893-3
- Berth-Jones J, Finlay AY, Zaki I, Tan B, Goodyear H, Lewis-Jones S, et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. Journal of the American Academy of Dermatology 1996;34:1016-1021 https://doi.org/10.1016/S0190-9622(96)90281-9
- Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. British Journal of Dermatology 2002;147:324-330 https://doi.org/10.1046/j.1365-2133.2002.04989.x
- Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. Journal of the American Academy of Dermatology 2013;68:29-35 https://doi.org/10.1016/j.jaad.2012.07.001
- Schram ME, Roekevisch E, Leeflang MMG, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. Journal of Allergy and Clinical Immunology 2011;128:353-359 https://doi.org/10.1016/j.jaci.2011.03.024
- Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. The Lancet 2006;367:839-846 https://doi.org/10.1016/S0140-6736(06)68340-2
- Ballester I, Silvestre J, Perez-Crespo M, Lucas A. Severe adult atopic dermatitis: treatment with mycophenolate mofetil in 8 patients. Actas Dermo-Sifiliograficas (English Edition) 2009;100:883-887 https://doi.org/10.1016/S1578-2190(09)70559-1
- Haeck IM, Knol MJ, ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. Journal of the American Academy of Dermatology 2011;64:1074-1084 https://doi.org/10.1016/j.jaad.2010.04.027
- Heller M, Shin H, Orlow S, Schaffer J. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. British Journal of Dermatology 2007;157:127-132 https://doi.org/10.1111/j.1365-2133.2007.07947.x
- D'erme AM, Milanesi N, Agnoletti AF, Maio V, Massi D, Gola M. Efficacy of treatment with oral alitretinoin in patient suffering from lichen simplex chronicus and severe atopic dermatitis of hands. Dermatologic therapy 2014;27:21-23 https://doi.org/10.1111/dth.12035
- Broshtilova V, Gantcheva M. Therapeutic Hotline: Cysteinyl leukotriene receptor antagonist montelukast in the treatment of atopic dermatitis. Dermatol Ther 2010;23:90-93 https://doi.org/10.1111/j.1529-8019.2009.01295.x
- Holme H, Winckworth LC. Montelukast can reduce the severity and extent of atopic dermatitis. J Paediatr Child Health 2013;49:412-415 https://doi.org/10.1111/jpc.12202
- Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol 2014;133:429-438 https://doi.org/10.1016/j.jaci.2013.07.049
- Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. Journal of Allergy and Clinical Immunology 2011;127:S1-S55 https://doi.org/10.1016/j.jaci.2010.09.034
- Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. Journal of Allergy and Clinical Immunology 2013;132:110-117 https://doi.org/10.1016/j.jaci.2013.02.044
- Bussmann C, Bockenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? Journal of allergy and clinical immunology 2006;118:1292-1298 https://doi.org/10.1016/j.jaci.2006.07.054
- Tintle S, Shemer A, Suarez-Farinas M, Fujita H, Gilleaudeau P, Sullivan-Whalen M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. Journal of Allergy and Clinical Immunology 2011;128:583-593. e584 https://doi.org/10.1016/j.jaci.2011.05.042
- Gambichler T, Terras S, Kreuter A. Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: facts and controversies. Clinics in dermatology 2013;31:438-454 https://doi.org/10.1016/j.clindermatol.2013.01.011
- Grundmann SA, Beissert S. Modern aspects of phototherapy for atopic dermatitis. J Allergy (Cairo) 2012;2012:121797
- Tay YK, Morelli JG, Weston WL. Experience with UVB phototherapy in children. Pediatr Dermatol 1996;13:406-409 https://doi.org/10.1111/j.1525-1470.1996.tb00711.x
- Werfel T. Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018. Curr Opin Allergy Clin Immunol 2018;18:432-437 https://doi.org/10.1097/ACI.0000000000000477
- Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371:130-139 https://doi.org/10.1056/NEJMoa1314768
- Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 2016;375:2335-2348 https://doi.org/10.1056/NEJMoa1610020
- Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 2018;78:S28-S36 https://doi.org/10.1016/j.jaad.2017.12.022
- Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017;389:2287-2303 https://doi.org/10.1016/S0140-6736(17)31191-1
- de Bruin-Weller M, Thaci D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol 2018;178:1083-1101 https://doi.org/10.1111/bjd.16156
- Han Y, Chen Y, Liu X, Zhang J, Su H, Wen H, et al. Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2017;140:888-891e886 https://doi.org/10.1016/j.jaci.2017.04.015
- Wang FP, Tang XJ, Wei CQ, Xu LR, Mao H, Luo FM. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. J Dermatol Sci 2018;90:190-198 https://doi.org/10.1016/j.jdermsci.2018.01.016
- Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005;60:693-696 https://doi.org/10.1111/j.1398-9995.2005.00791.x
- Khattri S, Brunner PM, Garcet S, Finney R, Cohen SR, Oliva M, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol 2017;26:28-35 https://doi.org/10.1111/exd.13112
- Saeki H, Kabashima K, Tokura Y, Murata Y, Shiraishi A, Tamamura R, et al. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study. Br J Dermatol 2017;177:419-427 https://doi.org/10.1111/bjd.15493
- Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. N Engl J Med 2017;376:826-835 https://doi.org/10.1056/NEJMoa1606490
- Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008;121:122-128 https://doi.org/10.1016/j.jaci.2007.11.016
- Sediva A, Kayserova J, Vernerova E, Polouckova A, Capkova S, Spisek R, et al. Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 2008; 121:1515-1516; author reply 1516-1517 https://doi.org/10.1016/j.jaci.2008.03.007
- Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010;8:990-998
- Hotze M, Baurecht H, Rodriguez E, Chapman-Rothe N, Ollert M, Folster-Holst R, et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 2014;69:132-135 https://doi.org/10.1111/all.12234
- Lacombe Barrios J, Begin P, Paradis L, Hatami A, Paradis J, Des Roches A. Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective. J Am Acad Dermatol 2013;69:832-834 https://doi.org/10.1016/j.jaad.2013.05.035
- Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 2013;162:89-93 https://doi.org/10.1159/000350486
- Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016;138:336-349 https://doi.org/10.1016/j.jaci.2016.06.010
- Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taieb A, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 2018;78:863-871 e811 https://doi.org/10.1016/j.jaad.2018.01.017
- Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol 2018
- Peng W, Novak N. Recent developments in atopic dermatitis. Curr Opin Allergy Clin Immunol 2014;14:417-422 https://doi.org/10.1097/ACI.0000000000000094
- Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. J Am Acad Dermatol 2018;78:872-881 e876 https://doi.org/10.1016/j.jaad.2018.01.016
- Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple- dose study. J Am Acad Dermatol 2018
- Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 2015;73:395-399 https://doi.org/10.1016/j.jaad.2015.06.045
- Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol 2012;148:890-897
- Kim SO, Ah YM, Yu YM, Choi KH, Shin WG, Lee JY. Effects of probiotics for the treatment of atopic dermatitis: a meta-analysis of randomized controlled trials. Ann Allergy Asthma Immunol 2014;113:217-226 https://doi.org/10.1016/j.anai.2014.05.021
- Panduru M, Panduru NM, Salavastru CM, Tiplica GS. Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies. J Eur Acad Dermatol Venereol 2015;29:232-242 https://doi.org/10.1111/jdv.12496
- Morse NL, Clough PM. A meta-analysis of randomized, placebo-controlled clinical trials of Efamol evening primrose oil in atopic eczema. Where do we go from here in light of more recent discoveries? Curr Pharm Biotechnol 2006;7:503-524 https://doi.org/10.2174/138920106779116946
- Bamford JT, Ray S, Musekiwa A, van Gool C, Humphreys R, Ernst E. Oral evening primrose oil and borage oil for eczema. Cochrane Database Syst Rev 2013:CD004416
- Camargo CA, Jr., Ganmaa D, Sidbury R, Erdenedelger K, Radnaakhand N, Khandsuren B. Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children. J Allergy Clin Immunol 2014;134:831-835 e831 https://doi.org/10.1016/j.jaci.2014.08.002
- Peroni DG, Piacentini GL, Cametti E, Chinellato I, Boner AL. Correlation between serum 25-hydroxyvitamin D levels and severity of atopic dermatitis in children. Br J Dermatol 2011;164:1078-1082 https://doi.org/10.1111/j.1365-2133.2010.10147.x
- Chiu YE, Havens PL, Siegel DH, Ali O, Wang T, Holland KE, et al. Serum 25-hydroxyvitamin D concentration does not correlate with atopic dermatitis severity. J Am Acad Dermatol 2013;69:40-46 https://doi.org/10.1016/j.jaad.2013.01.010